| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:NCOA2_MAP2K3 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: NCOA2_MAP2K3 | KinaseFusionDB ID: KFG4075 | FusionGDB2.0 ID: KFG4075 | Hgene | Tgene | Gene symbol | NCOA2 | MAP2K3 | Gene ID | 10499 | 5606 | |
| Gene name | nuclear receptor coactivator 2 | mitogen-activated protein kinase kinase 3 | ||||||||||
| Synonyms | GRIP1|KAT13C|NCoA-2|SRC2|TIF2|bHLHe75 | MAPKK3|MEK3|MKK3|PRKMK3|SAPKK-2|SAPKK2 | ||||||||||
| Cytomap | 8q13.3 | 17p11.2 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | nuclear receptor coactivator 2class E basic helix-loop-helix protein 75glucocorticoid receptor-interacting protein-1p160 steroid receptor coactivator 2transcriptional intermediary factor 2 | dual specificity mitogen-activated protein kinase kinase 3MAP kinase kinase 3MAPK/ERK kinase 3MAPKK 3MEK 3SAPK kinase 2stress-activated protein kinase kinase 2 | ||||||||||
| Modification date | 20240305 | 20240403 | ||||||||||
| UniProtAcc | Q15596 | P46734 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000267974, ENST00000452400, ENST00000524223, | ENST00000316920, ENST00000342679, ENST00000361818, ENST00000534743, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: NCOA2 [Title/Abstract] AND MAP2K3 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | NCOA2(71172635)-MAP2K3(21213574), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | NCOA2 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 9430642|11265755 |
| Tgene | MAP2K3 | GO:0031098 | stress-activated protein kinase signaling cascade | 8622669 |
| Tgene | MAP2K3 | GO:0045860 | positive regulation of protein kinase activity | 11980910 |
| Tgene | MAP2K3 | GO:0045893 | positive regulation of DNA-templated transcription | 11980910 |
| Kinase Fusion gene breakpoints across NCOA2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across MAP2K3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChiTaRS5.0 | BG674032 | NCOA2 | chr8 | 71172635 | MAP2K3 | chr17 | 21213574 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:71172635/:21213574) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| NCOA2 | MAP2K3 |
| FUNCTION: Transcriptional coactivator for steroid receptors and nuclear receptors (PubMed:8670870, PubMed:23508108, PubMed:9430642). Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1) (PubMed:8670870, PubMed:23508108, PubMed:9430642). Required with NCOA1 to control energy balance between white and brown adipose tissues (PubMed:8670870, PubMed:23508108, PubMed:9430642). Critical regulator of glucose metabolism regulation, acts as a RORA coactivator to specifically modulate G6PC1 expression (PubMed:8670870, PubMed:23508108, PubMed:9430642). Involved in the positive regulation of the transcriptional activity of the glucocorticoid receptor NR3C1 by sumoylation enhancer RWDD3 (PubMed:23508108). Positively regulates the circadian clock by acting as a transcriptional coactivator for the CLOCK-BMAL1 heterodimer (By similarity). {ECO:0000250|UniProtKB:Q61026, ECO:0000269|PubMed:23508108, ECO:0000269|PubMed:8670870, ECO:0000269|PubMed:9430642}. | FUNCTION: Dual specificity kinase. Is activated by cytokines and environmental stress in vivo. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in the MAP kinase p38. Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14. {ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8622669}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of NCOA2_MAP2K3 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| MAP2K3 | P46734 | human | MAP2K3 | P46734 | S218 | IsGyLVDsVAKtMDA | Pkinase |
| MAP2K3 | P46734 | human | MAPK13 | O15264 | T180 | RHADAEMtGyVVtRW | Pkinase |
| MAP2K3 | P46734 | human | MAPK14 | Q16539 | T180 | RHtDDEMtGyVAtRW | Pkinase |
| MAP2K3 | P46734 | human | MAPK13 | O15264 | Y182 | ADAEMtGyVVtRWYR | Pkinase |
| MAP2K3 | P46734 | human | MAP2K3 | P46734 | T222 | LVDsVAKtMDAGCKP | Pkinase |
| MAP2K3 | P46734 | human | MAPK14 | Q16539 | Y182 | tDDEMtGyVAtRWYR | Pkinase |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| MAP2K3 | ID | Description | 0.00e+00 |
| MAP2K3 | GO:0035331 | negative regulation of hippo signaling | 1.75e-04 |
| MAP2K3 | GO:0051403 | stress-activated MAPK cascade | 1.75e-04 |
| MAP2K3 | GO:0031098 | stress-activated protein kinase signaling cascade | 1.75e-04 |
| MAP2K3 | GO:0035330 | regulation of hippo signaling | 3.63e-04 |
| MAP2K3 | GO:0035329 | hippo signaling | 8.44e-04 |
| MAP2K3 | GO:0038066 | p38MAPK cascade | 1.19e-03 |
| MAP2K3 | GO:0035924 | cellular response to vascular endothelial growth factor stimulus | 1.77e-03 |
| MAP2K3 | GO:0034644 | cellular response to UV | 2.23e-03 |
| MAP2K3 | GO:0090398 | cellular senescence | 2.96e-03 |
| MAP2K3 | GO:0071482 | cellular response to light stimulus | 3.34e-03 |
| MAP2K3 | GO:0071322 | cellular response to carbohydrate stimulus | 4.25e-03 |
| MAP2K3 | GO:0009411 | response to UV | 4.25e-03 |
| MAP2K3 | GO:0071478 | cellular response to radiation | 5.56e-03 |
| MAP2K3 | GO:0071222 | cellular response to lipopolysaccharide | 7.78e-03 |
| MAP2K3 | GO:0009743 | response to carbohydrate | 7.78e-03 |
| MAP2K3 | GO:0071219 | cellular response to molecule of bacterial origin | 7.87e-03 |
| MAP2K3 | GO:0071216 | cellular response to biotic stimulus | 9.10e-03 |
| MAP2K3 | GO:0018105 | peptidyl-serine phosphorylation | 1.06e-02 |
| MAP2K3 | GO:0018209 | peptidyl-serine modification | 1.10e-02 |
| MAP2K3 | GO:0009416 | response to light stimulus | 1.11e-02 |
| MAP2K3 | GO:0071214 | cellular response to abiotic stimulus | 1.12e-02 |
| MAP2K3 | GO:0104004 | cellular response to environmental stimulus | 1.12e-02 |
| MAP2K3 | GO:0032496 | response to lipopolysaccharide | 1.16e-02 |
| MAP2K3 | GO:0002237 | response to molecule of bacterial origin | 1.25e-02 |
| MAP2K3 | GO:0050727 | regulation of inflammatory response | 1.50e-02 |
| MAP2K3 | GO:0009314 | response to radiation | 1.50e-02 |
| MAP2K3 | GO:0070391 | response to lipoteichoic acid | 1.50e-02 |
| MAP2K3 | GO:0071223 | cellular response to lipoteichoic acid | 1.50e-02 |
| MAP2K3 | GO:0071493 | cellular response to UV-B | 1.74e-02 |
| MAP2K3 | GO:0001819 | positive regulation of cytokine production | 1.82e-02 |
| MAP2K3 | GO:0051770 | positive regulation of nitric-oxide synthase biosynthetic process | 2.04e-02 |
| MAP2K3 | GO:0090336 | positive regulation of brown fat cell differentiation | 2.04e-02 |
| MAP2K3 | GO:1901741 | positive regulation of myoblast fusion | 2.04e-02 |
| MAP2K3 | GO:0010831 | positive regulation of myotube differentiation | 2.10e-02 |
| MAP2K3 | GO:0071243 | cellular response to arsenic-containing substance | 2.16e-02 |
| MAP2K3 | GO:0001502 | cartilage condensation | 2.16e-02 |
| MAP2K3 | GO:0051767 | nitric-oxide synthase biosynthetic process | 2.16e-02 |
| MAP2K3 | GO:0051769 | regulation of nitric-oxide synthase biosynthetic process | 2.16e-02 |
| MAP2K3 | GO:0010224 | response to UV-B | 2.16e-02 |
| MAP2K3 | GO:0032495 | response to muramyl dipeptide | 2.16e-02 |
| MAP2K3 | GO:1901739 | regulation of myoblast fusion | 2.16e-02 |
| MAP2K3 | GO:0098743 | cell aggregation | 2.29e-02 |
| MAP2K3 | GO:0060143 | positive regulation of syncytium formation by plasma membrane fusion | 2.29e-02 |
| MAP2K3 | GO:0035994 | response to muscle stretch | 2.29e-02 |
| MAP2K3 | GO:0070935 | 3'-UTR-mediated mRNA stabilization | 2.29e-02 |
| MAP2K3 | GO:0090335 | regulation of brown fat cell differentiation | 2.29e-02 |
| MAP2K3 | GO:0099560 | synaptic membrane adhesion | 2.42e-02 |
| MAP2K3 | GO:0060045 | positive regulation of cardiac muscle cell proliferation | 2.58e-02 |
| MAP2K3 | GO:0060142 | regulation of syncytium formation by plasma membrane fusion | 2.58e-02 |
Top |
Related Drugs to NCOA2_MAP2K3 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning NCOA2-MAP2K3 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to NCOA2_MAP2K3 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |